Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model

Rose Dicovitsky; Jill T. Schappa; Ashley J. Schulte; Haeree P. Lang; Ellen Marie Kuerbitz; Sarah Roberts; Taylor A. DePauw; Mitzi Lewellen; Amber L. Winter; Kathy Stuebner; Michelle T. Buettner; Kelly Reid; Kelly Bergsrud; Sara Pracht; Andrea Chehadeh; Caitlin Feiock; M. Gerard O’Sullivan; Tim Carlson; Alexandra R. Armstrong; Danielle Meritet; Michael S. Henson; Brenda J. Weigel; Jaime F. Modiano; Antonella Borgatti; Daniel A. Vallera

doi:10.3390/toxins16090376

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only emerging, so neither their efficacy nor toxicity is fully established. Recombinant eBAT was created by combining cytokines EGF and uPA on the same single-chain molecule with truncated

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dicovitsky et al. (2024) studied this question.

synapsesocial.com/papers/68e5aef2b6db643587547f1e https://doi.org/10.3390/toxins16090376

View Full Paper

Ask AI

Bookmark

Share

Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model

Ask about this paper

Abstract

Discussion

Cite This Study

Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading